Assessment of agents for the treatment of head injury: Problems and pitfalls in trial design

CNS Drugs

Volumn 13, Issue 2, 2000, Pages 139-154

  Maas, Andrew I R ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; APTIGANEL; ELIPRODIL; NEUROPROTECTIVE AGENT; NIMODIPINE; SUPEROXIDE DISMUTASE MACROGOL; TIRILAZAD; TRIAMCINOLONE;

BIOMECHANICS; BRAIN PROTECTION; CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFICACY; DRUG SCREENING; HEAD INJURY; HUMAN; LIPID PEROXIDATION; NERVE CELL LESION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OUTCOMES RESEARCH; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

EID: 0034008413     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200013020-00007     Document Type: Review

References (98)

1. Grumme TH, Baethmann A, Kolodziejczyk D, et al. Treatment of patients with severe head injury by triamcinolone: a prospective, controlled multicenter clinical trial of 396 cases. Res Exp Med 1995; 195: 217-29
2. Bailey I, Bell A, Gray J, et al. A trial of the effect of Nimodipine on outcome after head injury. Acta Neurochir (Wien) 1991; 110: 97-105
3. The European Study Group on Nimodipine in Severe Head Injury. A multicenter trial of the efficacy of nimodipine on outcome after severe head injury. J Neurosurg 1994; 80 (5): 797-804
4. Harders A, Kakarieka A, Braakman R. Traumatic subarachnoid hemorrhage and its treatment with nimodipine. J Neurosurg 1996; 85 (1): 82-9
5. Young B, Runge JW, Waxman KS, et al. Effects of pergorgotein on neurologic outcome of patients with severe head injury. A multicenter, randomized controlled trial. JAMA 1996; 276: 538-43
6. Straw RN, Means ED, Kitt TM, et al. Preliminary efficacy and safety results from Protocol P/2700/0017: tirilazad mesylate in the treatment of acute head injury (North American study) - technical report. Kalamazoo (MI): Pharmacia & Upjohn Co., 1998
7. Marshall LF, Maas AIR, Marshall SB, et al. A multicenter trial on the efficacy of tirilazad mesylate in cases of head injury. J Neurosurg 1998; 89: 519-25
8. Data on file, Synthelabo, 1997
9. Morris GF, Bullock R, Marshall SB, et al. Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. The Selfotel Investigators. J Neurosurg 1999; 91 (5): 737-43
10. Cambridge Neuroscience/European Brain Injury Consortium. Efficacy and safety of Cerestat (Aptiganel HCL) as a neuroprotective following severe traumatic brain injury. Cambridge (MA): Cambridge Neuroscience/Glasgow: European Brain Injury Consortium, 1998. (Data on file)
11. Novartis/European Brain Injury Consortium. Prospective, randomized, double blind, placebo controlled study of a competitive glutamate NMDA receptor antagonist (SDZ EAA 494, D-CPP-ene) in patients with a severe head injury. Basel: Novartis/Glasgow: European Brain Injury Consortium, 1999. (Data on file)
12. Teasdale G, Jennett B. Assessment of impaired coma and consciousness. A practical scale. Lancet 1974; II (7872): 81-4
13. Jones PA, Andrews PA, Midgley S, et al. Measuring the burden of secondary insults in head injured patients during intensive care. J Neurosurg Anesthesiol 1994; 6: 4-14
14. Gentleman D. Causes and effects of systemic complications among severely head-injured patients transferred to a neurosurgical unit. Int Surg 1992; 77: 297-302
15. Murray GD, Teasdale GM, Braakman R, et al. The European brain injury consortium survey of head injuries. Acta Neurochir (Wien) 1999; 141: 223-36
16. Stocchetti N, Furlan A, Volta F. Hypoxemia and arterial hypotension at the accident scene in head injury. J Trauma 1996; 40 (5): 764-7
17. Chesnut RM, Marshall LF, Klauber MR, et al. The role of secondary brain damage in determining outcome from severe head injury. J Trauma 1993; 34: 216-22
18. Fearnside MR, Cook RJ, McDougall P, et al. The Westmead head injury project outcome in severe head injury. A comparative analysis of prehospital, clinical and CT variables. Br J Neurosurg 1993; 7: 267-79
19. 2 and neurologic outcome in head injured patients. J Neurotrauma 1992; 9: S349-58
20. Teasdale GM, Graham DI. Cranial cerebral trauma: protection and retrieval of the neuronal population after injury. Neurosurgery 1998; 43 (4): 723-37
21. Maxwell WL, Povlishock JT, Graham DI. A mechanistic analysis of nondisruptive axonal injury: a review. J Neurotrauma 1997; 14: 419-40
22. Kampfl A, Posmantur RM, Zhao X, et al. Mechanisms of calpain proteolysis following traumatic brain injury: implications for pathology and therapy: a review and update. J Neurotrauma 1997; 14 (3): 121-34
23. Saatman KE, Murai H, Bartus RT, et al. Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury. Proc Natl Acad Sci U S A 1996; 93: 3428-33
24. Graham DI, Ford I, Adams JH, et al. Ischemic brain damage is still common in fatal non missile head injury. J Neurol Neurosurg Psychiatry 1989; 52: 346-50
25. Ross DT, Graham DI, Adams JH. Selective loss of neurons from the thalamic reticular nucleus following severe human head injury. J Neurotrauma 1993; 10: 151-65
26. Bouma GJ, Muizelaar JP, Stringer WA, et al. Ultra early evaluation of regional cerebral blood flow in severely head injured patients using xenon enhanced computerized tomography. J Neurosurg 1992; 77: 360-8
27. Van Santbrink H, Maas AIR, Avezaat CJJ. Continuous monitoring of partial pressure of brain tissue oxygen in patients with severe head injury. Neurosurgery 1996; 38: 21-31
28. Caron MH. PET/SPECT imaging in head injury. In: Narayan RK, Wilberger JE, Povlishock JT, editors. Neurotrauma. New York (NY): McGraw-Hill, 1996: 163-8
29. Hovda DA, Lee SM, Smith ML, et al. The neurochemical and metabolic cascade following brain injury: moving from animal models to man. J Neurotrauma 1995; 12: 903-6
30. Schröder ML, Muizelaar JP, Bullock MR, et al. Focal ischaemia due to traumatic contusion documented by stable xenon CT and ultrastructural studies. J Neurosurg 1995; 82: 966-71
31. Schröder ML, Muizelaar JP, Kuta AJ. Documented reversal of global ischaemia immediately after removal of an acute subdural haematoma: report of 2 cases. J Neurosurg 1994; 80: 324-7
32. Bullock R, Zauner A, Woodward JJ, et al. Factors affecting excitatory amino acid release following severe human head injury. J Neurosurg 1998; 89: 507-18
33. Katayama Y, Mori T, Maeda T, et al. Pathogenesis of the mass effect of cerebral contusions: rapid increase in osmolality within the contusion necrosis. Acta Neurochir Suppl. 1998; 71: 289-92
34. Barzo P, Maramarou A, Fatouros P, et al. Biphasic pathophysiological response of vasogenic and cellular edema in traumatic brain swelling. Acta Neurochir Suppl. (Wien) 1997; 70: 119-22
35. Lang DA, Hadley DM, Teasdale GT, et al. Gadolinium DTPA enhanced magnetic resonance imaging in acute head injury. Acta Neurochir (Wien) 1991; 109: 5-11
36. Rosner MJ, Rosner SD, Johnson AH. Cerebral perfusion pressure: management protocol and clinical resulls. J Neurosurg 1995; 83: 949-62
37. Cruz J, Miner ME, Allen SJ, et al. Continuous monitoring of cerebral oxygenation in acute brain injury: assessment of cerebral hemodynamic reserve. Neurosurgery 1991; 29: 743-9
38. Asgeirsson B, Grände P-O, Nordström C-H. The Lund concept of post traumatic brain edema therapy. Acta Anaesth Scand 1995; 39: 112-4
39. 45Ca autoradiographic study. Brain Res 1993; 624: 94-102
40. Shapira Y, Yadid G, Cotev S, et al. Accumulation of calcium in brain following head trauma. Neurol Res 1989; 11: 169-72
41. Siesjo BK, Bengtsson F. Calcium fluxes, calcium antagonists, and calcium-related pathology in brain ischemia, hypoglycemia, and spreading depression: a unifying hypothesis. J Cereb Blood Flow Metab 1989; 9: 127-40
42. Robinson MJ, Teasdale GM. Calcium antagonists in the management of subarachnoid haemorrhage. Cerebrovasc Brain Metab Rev 1990; 2: 205-26
43. Fox AP, Nowycky MC, Tsien RW. Kinetic and pharmacological properties distinguishing three types of calcium currents in chick sensory neurones. J Physiol (Lond) 1987; 394: 149-72
44. Kakarieka A. Traumatic subarachnoid hemorrhage. Heidelberg: Springer-Verlag Berlin, 1997
45. Kakarieka, Schakel EH, Fritze J. Clinical experiences with nimodipine in cerebral ischemia. J Neural Transm 1994; 43 Suppl.: 13-21
46. Vinge E, Andersson K-E, Brandt L, et al. Pharmacokinetics of nimodipine in patients with aneurysmal subarachnoid haemorrhage. Eur J Clin Pharmacol 1986; 30: 421-5
47. Rämsch KD, Ahr G, Tettenborn D, et al. Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage. Neurochirurgia 1985; 28: 74-8
48. Hall ED, McCall JM, Means ED. Therapeutic potential of the lazaroids (21-aminosteroids) in acute central nervous system trauma, ischemia and subarachnoid hemorrhage. Adv Pharmacol 1994; 28: 221-68
49. Kontos HA, Povlishock J. Oxygen radicals in brain injury. CNS Trauma 1986; 2: 257-63
50. Braughler JM, Hall ED. Central nervous system trauma and stroke. I. Biochemical considerations for oxygen radical formation and lipid peroxidation. Free Radic Biol Med 1989; 6: 289-301
51. Hall ED, Braughler JM. Central nervous system trauma and stroke. II. Physiological and pharmacological evidence for the involvement of oxygen radicals and lipid peroxidation. Free Radic Biol Med 1989; 6: 303-13
52. Fleishaker JC, Peters GR, Cathcart KS. Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: I. Single-dose administration. J Clin Pharmacol 1993; 33: 175-81
53. Fleishaker JC, Peters GR, Cathcart KS, et al. Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: II. Multiple-dose administration. J Clin Pharmacol 1993; 33: 182-90
54. Benveniste H. The excitotoxic hypothesis in relation to cerebral ischaemia. Cerebrovasc Brain Metab Rev 1991; 3: 213-45
55. Onodera H, Araki T, Kogure K. Excitatory amino acid binding sites in the rat hippocampus after transient forebrain ischaemia. J Cereb Blood Flow Metab 1989; 9: 623-8
56. Simon RP, Swan JH, Griffieths T, et al. Blockade of N-methyl-D-aspartate receptors may protect against ischaemic damage in the brain. Science 1984; 226: 850-2
57. Zauner A, Bullock R. The role of excitatory amino acids in severe brain trauma: opportunities for therapy - a review. J Neurotrauma 1995; 12: 547-54
58. During MJ, Spencer DD. Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet 1993; 341: 1607-10
59. Rothman SM, Olney JW. Excitotoxicity and the NMDA receptor. Trends Neurosci 1987; 10: 299-302
60. Katayama Y, Maeda T, Koshinaga M, et al. Role of excitatory amino-acid mediated ionic fluxes in traumatic brain injury. Brain Pathol 1995; 5: 427-35
61. McIntosh TK, Saatman KE, Raghupathi R. Calcium and the pathogenesis of traumatic CNS injury: cellular and molecular mechanisms. Neuroscientist 1997; 3: 169-75
62. Faden AI, Demediuk P, Panter SS, et al. The role of excitatory amino acids on NMDA receptors in traumatic brain injury. Science 1989; 244: 798-800
63. Katayama Y, Becker DP, Tamura T, et al. Massive increase in extracellular potassium and indiscriminate release of glutamate following concussive brain injury. J Neurosurg 1990; 73: 889-900
64. Nilsson P, Hillered L, Ponten U, et al. Changes in cortical extracellular levels of energy-related metabolites and amino acids following concussive brain injury in rats. J Cereb Blood Flow Metab 1990; 10: 631-7
65. Palmer AM, Marion DW, Botscheller ML, et al. Traumatic brain injury-induced excitotoxicity assessed in a controlled cortical impact model. J Neurochem 1993; 61: 2015-24
66. Gennarelli TA, Adams JH, Graham DI. Excelleration induced head injury in the monkey. I: the model, its mechanical and physiological correlates. Acta Neuropathol 1981; Suppl. 7: 23-5
67. Dixon CE, Lyeth BC, Povlishock JT, et al. A fluid percussion model of experimental brain injury in the rat. J Neurosurg 1987; 67: 110-19
68. Sullivan HG, Martinez J, Becker DP. Fluid percussion model of mechanical brain injury in the cat. J Neurosurg 1976; 45: 520-34
69. McIntosh TK, Vink R, Noble LJ, et al. Traumatic brain injury in the rat: characterization of a lateral fluid percussion model. Neuroscience 1989; 28: 233-44
70. Dixon CE, Clifton GL, Lighthall JW, et al. A controlled cortical impact model of traumatic brain injury in the rat. J Neurosci Meth 1991; 39: 253-62
71. Feeney DM, Boyeson MG, Linn RT, et al. Responses to cortical injury: I. Methodology and local effects of contusions in the rat. Brain Res 1981; 211: 67-77
72. Marmarou A, Abd-Elfattah Foda MA, van den Brink WA, et al. A new model of diffuse brain injury in rats. Part I: Pathophysiology and biomechanics. J Neurosurg 1994; 80: 291-300
73. Germano B, Pitts L, Islinge N. Experimental brain trauma: effects of pre-injury treatment with nimodipine [abstract]. International Symposium on Calcium Antagonists: 1987 Feb 10-13; New York
74. Sanada T, Pitts LH, Nishimura M. The effect of nimodipine following experimental head injury in rats. In: Scriabine A, Teasdale GM, Tettenborn D, et al. editors. Nimodipine, pharmacological and clinical results in cerebral ischemia. Proceedings of the Second International Symposium on Nimodipine. Berlin: Springer-Verlag, 1990: 241-51
75. Hall ED, Yonkers PA, McCall JM. Effects of the 21-aminosteroid U-74006F on experimental head injury in mice. J Neurosurg 1988; 68: 456-61
76. Sanada T, Nakamura, Nishimura MC, et al. Effect of U-74006F on neurological function and brain edema after fluid percussion injury in rats. J Neurotrauma 1993; 10: 65-71
77. McIntosh TK, Thomas M, Smith D. The novel 21-aminosteroid U-74006 attenuates cerebral edema and improves survival after brain injury in the rat. J Neurotrauma 1992; 9: 33-46
78. Dimlich RVW, Tornheim PA, Kindel RM, et al. Effects of a 21-aminosteroid (U-74006F) on cerebral metabolites and edema after severe experimental head trauma. Adv Neurol 1990; 52: 365-75
79. Hall ED, Smith SL, Andrus PK, et al. Direct measurement of increased hydroxyl radical levels and lipid peroxidation in experimental head injury and relationship to blood-brain barrier disruption [abstract]. J Neurotrauma 1993; 10 Suppl. 1: 87
80. Hall ED, Andrus PK, Yonkers PA. Brain hydroxyl radical generation in acute experimental head injury. J Neurochem 1993; 60: 588-94
81. Panter SS, Faden AI. Pretreatment with NMDA antagonists limits release of excitatory amino acids following traumatic brain injury. Neurosci Lett 1992; 136: 165-8
82. Sanada T, Pitts LH, Nishimura MC. The expression of heat shock protein after brain injury in the rat: combined effect of NMDA antagonist, voltage-dependent calcium blocker, and a free radical scavenger [abstract no. 552.12]. Soc Neurosci Abstr 1990; 16 (2): 1340
83. McIntosh TK, Smith DH, Hayes RL, et al. Role of excitatory amino acid neurotransmitters in the pathogenesis of traumatic brain injury. In: Simon RP, editor. Excitatory amino acids. Vol. 9. New York (NY): Thieme Medical Publishers Inc., 1992: 247-53. (Fidia Research Foundation Symposium Series)
84. Kuroda Y, Fujisawa H, Strebel S, et al. Effect of neuroprotective N-methyl-D-aspartate antagonists on increased intracranial pressure: studies in the rat acute subdural hematoma model. Neurosurgery 1994; 35: 106-12
85. Chen H, Bullock R, Graham DI, et al. Ischemic neuronal damage after acute subdural hematoma in the rat: effects of pretreatment with a glutamate antagonist. J Neurosurg 1991; 74: 944-50
86. Inglis F, Kuroda Y, Bullock R. Glucose hypermetabolism after acute subdural hematoma is ameliorated by a competitive NMDA antagonist. J Neurotrauma 1992; 9: 75-84
87. Bullock MR, Lyeth BG, Muizelaar JP. Current status of neuroprotection trials for traumatic brain injury: lessons from animal models and clinical studies. Neurosurgery 1999; 45: 207-20
88. Hogan J, Takizawa S, Hakim AM. In vitro binding of 3H Nimodipine ad 3H CGS 19755 to rat brain in forcal cerebral ischemia. Exp Neurol 1995; 134: 56-63
89. Fleishaker JC, Hulst-Pearson LK, Petrs GR. Effect of gender and menopausal status on the pharmacokinetics of tirilazad mesylate in healthy subjects. Am J Ther 1995; 2: 553-60
90. Fleishaker JC, Straw RN, Cross CJ. Pharmacokinetics of Tirilazad and U-89678m an active, reduced metabolite, following acute head trauma in adults. J Pharm Sci 1997; 86: 434-7
91. Choi SC, Barnes ThY. Predicting outcome in the head-injured patient. In: Narayan RK, Wilberger JE, Povlishok JT, editors. Neurotrauma. New York (NY): The McGraw-Hill Companies Inc., 1996: 779-92
92. Braakman R, Gelpke GJ, Habbema JDF, et al. Systematic selection of prognostic features in patients with severe head injury. Neurosurgery 1980; 6; 362-70
93. Jennett B, Teasdale GM, Braakman R, et al. Predicting outcome in individual patients after severe head injury. Lancet 1976; 1 (7968): 1031-4
94. Maas AIR, Steyerberg EW, Murray GD, et al. Why have recent trials of neuroprotective agents in head injury failed to show convincing efficacy? A pragmatic analysis and theoretical considerations. Neurosurgery 1999; 44 (6): 1286-98
95. Treasure T, MacRae. Minimisation: the platinum standard for trials? Randomization does not guarantee similarity of groups; minimisation does. Br Med J 1998; 317: 362-3
96. Machado SG, Murray GD, Teasdale GM, on behalf of the European Brain Injury Consortium. Evaluation of designs for clinical trials of neuroprotective agents in head injury. J Neurotrauma 1999; 16 (12): 1131-8
97. Jennett B, Bond M. Assessment of outcome after severe brain damage. A practical scale. Lancet 1975; 1: 480-4
98. Wilson JLT, Pettigrew LEL, Teasdale GM. Structured interviews for the Glasgow Outcome Scale and the extended Glasgow outcome scale: guidelines for their use. J Neurotrauma 1998: 15: 573-85